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ELOVL5 (Elongase of Very-Long Fatty Acid 5) gene encodes for an enzyme that
elongates long chain fatty acids, with a marked preference for polyunsaturated
molecules. In particular, it plays an essential role in the elongation of omega-
3 and omega-6 fatty acids, precursors for long-chain polyunsaturated fatty acids
(PUFAs). Mutations of ELOVL5 cause the spino-cerebellar ataxia type 38 (SCA38),
a rare autosomal neurological disease characterized by gait abnormality, dysarthria,
dysphagia, hyposmia and peripheral neuropathy, conditions well represented by a
mouse model with a targeted deletion of this gene (Elovl5−/− mice). However, the
expression pattern of this enzyme in neuronal and glial cells of the central nervous
system (CNS) is still uninvestigated. This work is aimed at filling this gap of knowledge
by taking advantage of an Elovl5-reporter mouse line and immunofluorescence analyses
on adult mouse CNS sections and glial cell primary cultures. Notably, Elovl5 appears
expressed in a region- and cell type-specific manner. Abundant Elovl5-positive cells
were found in the cerebellum, brainstem, and primary and accessory olfactory regions,
where mitral cells show the most prominent expression. Hippocampal pyramidal cells of
CA2/CA3 where also moderately labeled, while in the rest of the telencephalon Elovl5
expression was high in regions related to motor control. Analysis of primary glial cell
cultures revealed Elovl5 expression in oligodendroglial cells at various maturation steps
and in microglia, while astrocytes showed a heterogeneous in vivo expression of Elovl5.
The elucidation of Elovl5 CNS distribution provides relevant information to understand
the physiological functions of this enzyme and its PUFA products, whose unbalance is
known to be involved in many pathological conditions.
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INTRODUCTION
Polyunsaturated fatty acids (PUFAs) are fatty acids containing two or more double bonds on their
carbon chain, and are classified, depending on the position of the first double bond from the methyl
terminal end, in ω-6 PUFAs and ω-3 PUFAs. In addition to a structural role in membranes, various
PUFA metabolites also possess signaling functions, including roles in neurogenesis, neuronal
survival, synaptic activity and regulation of brain inflammation (Guillou et al., 2010; Bazinet and
Layé, 2014; Serhan et al., 2014). These multiple actions are the basis of the positive outcomes of
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PUFA-targeting treatments in various CNS pathological
conditions, such as Parkinson’s disease, Alzheimer’s disease and
Multiple sclerosis (Bousquet et al., 2011; Yanai, 2017; Penesová
et al., 2018; Hernando et al., 2019). In mammalian organisms,
essential fatty acids have to be introduced through the diet as
precursors and then metabolized into more complex derivatives,
by elongation and desaturation reactions performed by different
enzymes located in the endoplasmic reticulum (ER) (Moon et al.,
2009). A key and rate-controlling role is played by ELOVLs
(ELOngation of Very Long-chain fatty acids), which are elongase
enzymes responsible for and initial condensation reaction
necessary to elongate fatty acids (Leonard et al., 2004; Jakobsson
et al., 2006; Sassa and Kihara, 2014).
Seven ELOVL multi-pass transmembrane proteins have been
identified (ELOVL1-7) and each of them shows a particular
substrate preference: ELOVL1, ELOVL3, ELOVL6, and ELOVL7
elongate saturated or monounsaturated fatty acids, while
ELOVL2, ELOVL4, and ELOVL5 are more selective for very
long chain fatty acids (VLCF) and PUFAs (Moon et al., 2009).
ELOVL5, in particular, has the unique property to condense
a wide selection of PUFAs from 18 to 20 carbon atoms,
including linoleic (C18:2, n-6) acid to produce arachidonic
acid (C20:4, n- 6), α-linolenic (C18:3, n-3), and stearidonic
(C18:4, n-3) to produce eicosapentaenoic (EPA, C20:5, n-3) and
docosahexaenoic (DHA, C22:6, n-3) acids (Leonard et al., 2000;
Moon et al., 2009; Shikama et al., 2015).
Mutations in ELOVL genes has been linked to various
nervous system diseases. Indeed, ELOVL1 mutations lead
to hypomyelination, neuro-ichthyosis, spastic paraplegia and
optic atrophy (Kutkowska-Kaźmierczak et al., 2018; Mueller
et al., 2019). ELOVL4 mutations cause autosomal dominant
spinocerebellar ataxia (type 34; SCA34), erythrokeratodermia
variabilis (EKV) (Cadieux-Dion et al., 2014; Bourassa et al.,
2015; Ozaki et al., 2015) and autosomal dominant Stargardt-
like macular dystrophy (STGD3) (Bernstein et al., 2001; Edwards
et al., 2001; Zhang et al., 2001). ELOVL7 mutations have been
associated with Parkinson’s disease and multiple system atrophy
(Sailer et al., 2016; Li et al., 2018; Keo et al., 2020), while ELOVL2
polymorphisms were proposed to increase the susceptibility to
autism spectrum disorders (Sun et al., 2018).
Two ELOVL5 missense mutations [(c.214C > G (p.Leu72Val)
and c.689G > T (p.Gly230Val)] have been identified as the
genetic cause of the Spinocerebellar Ataxia 38 (SCA38) (Di
Gregorio et al., 2014). SCA38 is a rare form of autosomic
dominant neurological disorder characterized by gait ataxia,
nystagmus, peripheral neuropathy, hyposmia and pure cerebellar
atrophy (Borroni et al., 2016). Such pathological features were
recapitulated in a mouse model with a targeted deletion of
the Elovl5 gene (Elovl5−/−) showing motor coordination and
balance defects, loss of the sense of smell and a selective cerebellar
atrophy (Hoxha et al., 2017).
Such a variety of neurologic alterations associated with
mutations of different ELOVLs, might be explained by their
tissue-specific expression and tissue-specific role. While
ELOVL2, ELOVL7, and ELOVL1 have a restricted CNS
distribution (Tvrdik et al., 2000; Lein et al., 2007), Elovl4
expression is abundant and well characterized in both adult and
perinatal mouse brain (Sherry et al., 2017). In contrast, the Elovl5
expression pattern remains largely uninvestigated so far. This
work is aimed at mapping Elovl5 expression in the adult mouse
CNS with the final aim to provide relevant insights to understand
its role in specific CNS areas and cell types.
MATERIALS AND METHODS
Animals
Elovl5−/− mice have been kindly provided by Dr. Moon and
Dr. Horton of the UT Southwestern Medical Center (Moon
et al., 2009). Brains analyzed to study the expression of Elovl5
were collected from adult (6 to 12 months old) Elovl5−/−
and Elovl5+/− (C57/BL6J background) and wild type mice
(C57/BL6J) of both sexes bred in our Animal Facility at NICO
(Orbassano, Italy). All experimental procedures on adult mice
and on pups have been approved by the Ethical Committee of the
University of Torino and authorized by the Italian Ministry of
Health (authorization number: 161/2016-PR and 510/2020-PR).
Tissue Preparation
To assess Elovl5 expression in brain slices mice were anesthetized
using a cocktail of ketamine (100 mg/kg body weight)
and xylazine (10 mg/kg body weight) via intraperitoneal
injection. The mice were intracardially perfused initially with
a physiological solution (NaCl 0.9%) and then with 4%
paraformaldehyde in 0.12 M phosphate buffer, pH = 7.2–7.4.
Following perfusion, the brain and the spinal cord were removed
and stored at 4◦C for 24 h immersed in the same fixative and
later transferred to a solution made of 30% sucrose in 0.12
M phosphate buffer for few days. Perfused brains and spinal
cords were embedded in paraffin, cut into 5 µm-thick sagittal
slices and mounted on superfrost glass slides (Fisher Scientific,
Göteborg, Sweden) with Tris-glycerol supplemented with 10%
Mowiol (Calbiochem, LaJolla, CA, United States).
To assess Elovl5 expression in glial cells in vitro, postnatal
day 2 (P2) pups were cryoanesthetized in melting ice. The
experimental plan was designed according to the guidelines of
the NIH, the European Communities Council (2010/63/EU) and
the Italian Law for Care and Use of Experimental Animals
(DL26/2014). The study was conducted according to the
ARRIVE guidelines.
Magnetic-Activated Cell Sorting (MACS)
Isolation of Oligodendrocytes and Cell
Culture Procedures
To assess Elovl5 expression in glial cells in vitro, oligodendrocyte
progenitor cells (OPCs) were isolated from P2 mouse brain
(C57/BL6J background) by Magnetic-Activated Cell Sorting
(MACS; Miltenyi Biotech GmbH, Bergisch Gladbach, DE) as
in Boda et al. (2015). After tissue dissociation with the Neural
Tissue Dissociation Kit P (Miltenyi Biotech GmbH, Bergisch
Gladbach, DE), mouse OPCs were enriched by positive selection
using an anti-PDGFRα antibody conjugated to magnetic beads,
according to the manufacturer’s instructions (Miltenyi Biotech
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GmbH). MAC-sorted OPCs were then plated onto poly-D-
lysine (1 µg/ml, Sigma-Aldrich, Saint Louis, MS, United States)
coated glass coverslips in a proliferative medium including
Neurobasal, 1X B27 (Invitrogen, Milan, Italy), 2 mM L-glutamine
(Sigma-Aldrich, Saint Louis, MS, United States), 10 ng/ml
PDGF-BB, and 10 ng/ml human bFGF (Miltenyi Biotech
GmbH, Bergisch Gladbach, DE), or in differentiative medium
including Neurobasal, 1X B27 (Invitrogen, Milan, Italy), 2 mM
L-glutamine (Sigma-Aldrich, Saint Louis, MS, United States), 0.5
nM triiodothyronine (T3; Sigma-Aldrich). In all cases, purity of
the MACS-selected OPCs was verified by immunocytochemistry
(more than 95% of the cells were NG2+ at 6 h post-plating).
Microglial cells have been obtained by orbital shaking method
from mixed glial cell cultures and polarized toward either a
proinflammatory (M1) or pro-regenerative (M2) phenotype by
incubating with TNF-α (20 ng/ml) or IL-4 (20 ng/ml) (R&D,
Milan, Italy) for 48 h, as described in Lombardi et al. (2019).
Quantitative RT–PCR
Total RNA from cell cultures was extracted with the Directzol
RNA Miniprep kit (Zymo Research, Irvine, United States),
and reverse transcribed to cDNA with the High-Capacity
cDNA Archive kit (Thermo Fisher Scientific, Waltham,
United States). Quantitative Real Time RT-PCR was performed
as described in Sacco et al. (2010), with the pre-developed
Taqman assay #Rn01446631_m1 (Thermo Fisher Scientific,
Waltham, United States). A relative quantification approach
was used, according to the 2-ddCT method. β-actin (Taqman
assay #Rn00667869_m1; Thermo Fisher Scientific, Waltham,
United States) was used to normalize expression levels.
XGal Staining
To assess Elovl5 expression we first mapped β-galactosidase
activity in homozygous and heterozygous Elovl5 knock-out
mouse line where lacZ was included as a reporter under the
control of Elovl5 promoter. Floating slices (30 µm-thick brain
sagittal slices) were incubated overnight at 37◦C with a solution
containing 1 mg/ml X-gal, 0.02% Nonidet P-40, 0.01% sodium
deoxycholate, 2 mM MgCl2, 5 mM potassium ferricyanide,
and 5 mM potassium ferrocyanide (pH = 7.5). Subsequently,
the sections were mounted on gelatin-coated slides and let
air dry overnight. The next day the sections were counter-
stained with Nuclear Fast Red: mounted series were washed
for 2 min in distilled water and then stained in 0.1% NFR
(nuclear fast red) solution for 2 min. Sections were then
rinsed again in distilled water for 2 min, and subsequently
dehydrated using a series of alcohols: 50% (2 min), 75%
(2 min), 90% (2 min), and 100% (2 min). Afterward, the
gelatin- coated slides were immersed in xylene for 5 min and
finally a clear glass coverslip was applied using a permanent
mounting medium.
Immunofluorescence Reactions
Slides were incubated at 60◦C for 30 min to allow the embedded
tissue to firmly adhere to the glass slide. Following, paraffin
was removed by immerging three time the glass slides in xylol
(3 min each) and the tissue was hydrated using a series of
alcohols with decreasing graduation: 99% (three washes of 5
min each), 95% (three washes of 1 min each) 70% (three
washes of 1 min each). Slides were washes twice in H2O (1
min each) and placed for 40 min at 95◦C in citrate buffer
(pH = 6.0) for antigen retrieval. Following the antigen retrieval,
sections were washed twice in PBS (two quick washes) and
then incubated with blocking buffer (Normal Goat Serum 5%,
PBS 0.12 M pH = 7.4 and 1% Triton X100). Following, slides
were washed with PBS for three times and then incubated
with a cocktail containing: monoclonal primary anti-Elovl5
antibody made in rabbit (1:300 NBP2-33500, Novus biologicals,
Centennial, United States), 1.5% NGS and PBS+ overnight at
room temperature (RT) in a humid dark chamber. The following
morning the tissues was washed three times with PBS (5 min
each) and incubated with biotinylated secondary antibody anti
rabbit (1:200, Vector Labs, Burlingame, United States) for 2 h.
Slides were then washed three times with PBS (5 min each) and
incubated with streptavidin-HRP (1:100, PerkinElmer, Milano,
IT), and PBS+ for 1 h at RT. Following the incubation, sections
were washed three time in PBS (5 min each) and incubated
with Tyramide-FITC (1:100 PerkinElmer, Milano, IT) for 5 min
at RT in the humid dark chamber. After a 5-min incubation
with DAPI (1:1,000, Fluka, Saint Louis, United States), when dry,
glass coverslip was applied using Mowiol (Calbiochem, LaJolla,
CA, United States).
For immunocytochemistry on cell cultures, after 7 days in vitro
cells were fixed for 20 min at RT with 4% PFA in 0.1 M PB
and labeled with anti-AN2 (rat homologue of NG2, 1:100; kind
gift of Miltenyi Biotech GmbH, Bergisch Gladbach, DE, and
FIGURE 1 | Expression of Elovl5 in the central nervous system. XGal staining
(blue) indicates an ubiquitary expression of Elovl5 gene in forebrain (A),
cerebellum and brainstem (B), spinal cord (C). MOB, Main Olfactory Bulb;
CTX, Cortex; HPF, Hippocampus; MB, midbrain; TH, thalamus; HY,
Hypothalamus; CNU, cerebral nuclei. Scalebars: (A,B) 500 µm and
(C) 50 µm.
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TABLE 1 | Levels of expression of the ELovl5 gene (XGAL) and of the Elovl5
protein (immunofluorescence) in the central nervous system.
XGAL Immunofluorescence
Olfactory bulb Glomerular layer – –
Outer plexiform layer – SP
Mitral cell layer +++ +++
Internal plexiform layer – –




Pyriform cortex +++ +++
Olfactory tubercle + ++







Lateral septum ++ +




Dentate gyrus –* –*
Hylar neurons ++ ++
Subiculum + +
Neocortex Layer I ++ ++
Layer II/III ++ ++
Layer IV ++ ++
Layer V ++ ++
Layer VI + +







Globus pallidus – ++








Thalamus Reticular nuclei ++ +++















Hypothalamus Tuberal nucleus ++ ++




Lateral hypothalamic area ++ ++/+
(Continued)





Mammillary nucleus ++ ++
Preoptic area ++ ++
Midbrain Inferior colliculus + +
Superior colliculus ++ ++
Red nucleus +++ +++




Pons Tegmental nuclei ++ ++++




Supraolivary complex +++ +++
Pontine reticular nuclei ++ ++
Medulla Vestibular nuclei ++++ ++++




Nucleus of solitary tract ++ ++
Inferior olivary complex ++++ +++
Cerebellum Purkinje cells +++ +++
Molecular layer SP SP
Granular layer SP SP







Motorneurons–lamina X +++ +++
Signals were rated as ++++, very high to intense; +++, intense; ++, moderate; +,
low; –, not detectable; SP, labeling restricted to sparse cells.
* positive cells in the subgranular region.
Prof. J. Trotter, Johannes Gutemberg University of Mainz, DE),
-MBP (Smi-99 clone, 1:1,000 Sternberger), -Iba1 (1:1,000; Wako
Chemicals, Richmond, VA), -Elovl5 (1:300; NBP2-33500, Novus
biologicals, Centennial, United States) antibodies overnight
at 4◦C in PBS with 0.25% Triton-X. Then, coverslips were
incubated with Alexa488- and Alexa555- conjugated secondary
antibody (Molecular Probes, Eugene, Oregon) for 1-h RT.
After a 5-min incubation with DAPI (1:1,000, Fluka, Saint
Louis, United States), coverslips were mounted with Tris-
glycerol supplemented with 10% Mowiol (Calbiochem, LaJolla,
CA, United States).
Images Acquisition and Processing
Slides were scanned with Slide-Scanner Axiscan Z1 (ZEISS,
Oberkochen, DE) both at low and high magnification (5x
and 20x). Images obtained were then modified and adapted
in color, contrast and brightness with Zen Software 2.1
(ZEISS, Oberkochen, DE). All the structures were analyzed and
recognized by using the Interactive Atlas Viewer [IAV; Allen
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Human Brain Atlas–Allen Institute for Brain Science. Mouse
Brain Atlas (internet)1.].
Whereas, cell coverslipped cultures were examined using an
E-800 Nikon microscope (Nikon, Melville, NY) connected to a
color CCD Camera and a Leica TCS SP5 (Leica Microsystems,
Wetzlar, DE) confocal microscope. Adobe Photoshop 6.0 (Adobe
Systems, San Jose, CA, United States) was used to assemble
the final plate.
Statistics
Statistical analyses were carried out with GraphPad Prism
7 (GraphPad sofware, Inc). The Shapiro–Wilk test was first
applied to test for a normal distribution of the data. Since
data were not normally distributed, Mann-Whitney U-test (to
compare two groups) and Kruskal-Wallis test (for multiple
1http://mouse.brain-map.org
group comparisons) were used. In all instances, P < 0.05
was considered as statistically significant. Histograms represent
mean± standard error (SE).
RESULTS
Elovl5 Gene Expression in the Central
Nervous System
In the lacZ reporter mouse, XGal staining revealed a widespread
expression with some region-specific differences (Figure 1,
Supplementary Figure 1, and Table 1). It is important to note
that the XGal staining observed in Elovl5 lacZ reporter mouse
reflected the in-situ hybridization published in Allen Mouse
Brain Atlas. Specifically, in the telencephalon, a prominent
labeling was found in the olfactory bulb (mitral cell layer,
Figure 1A), in the neocortex, in the hippocampus (Figure 1A)
FIGURE 2 | Elovl5 distribution in olfactory regions. (A) In the olfactory bulb, immunohistochemical labeling for Elovl5 (green) and DAPI (blue), shows a strong signal in
mitral cells (mi) and in the glomerular layer (gl), while cells belonging to the granule cell layer (gcl) are negative. (B) The olfactory tubercle (OT) (shown at high
magnification) shows a predominant expression of Elovl5 (green) in layer II and layer III neurons. (C) In layer II neurons of the accessory olfactory nucleus (AON) a
moderate presence of the enzyme is detected. (D) The accessory olfactory bulb shows a similar signal as the one detected in the main bulb, with a high intensity in
mitral cells (mi) and no signal in the granule cell layer (gcl). MOB, Main Olfactory Bulb; mi, mitral cells; gl, glomerular layer; opl, outer plexiform layer; gcl, granular cell
layer; OT, Olfactory Tubercle; AON, Anterior Olfatory Nucleus; AOB, Accessory Olfactory Bulb. Scalebars: (A,C) 200 µm, (B) 100 µm, and (D) 50 µm.
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and in the midbrain (Figure 1B). The thalamus showed a less
pronounced, moderate XGal labeling, with the exception of
a strong expression in the reticular nucleus (Figure 1A). As
previously shown (Hoxha et al., 2017), in the cerebellum Purkinje
cells and deep cerebellar nuclei were the most expressing cell
types (Figure 1B). Interestingly, we also found several labeled
cells in the cerebellar white matter, in the granular layer and in the
deeper part of the molecular layer. In the spinal cord, we observed
a pronounced labeling in the gray matter, in neurons of different
cell body size (Figure 1C).
Elovl5 Protein Distribution in Brain
Regions
Protein localization was analyzed in wild-type mice by
immunofluorescence labeling throughout different brain
FIGURE 3 | Elovl5 expression in cortical and subcortical regions. (A) In the hippocampus, Elovl5 (green) is strongly expressed by CA2 and CA3, in a moderate way
by CA1, while it is not present in dentate gyrus. Oriens, radiatum, and hilar interneurons are strongly labeled. Cell nuclei are counterstained by DAPI (blue). (B) In the
neocortex Elovl5 labeling is present in a moderately strong way in layers II/III, IV and V. In layer VI, neurons display a weak intensity staining. (C) In the amygdala
Elovl5 expression is more prominent in the cortical areas than in medial ones. (D) The claustrum is moderately positive for Elovl5 staining, while piriform and
endopiriform cortex show a strong signal. HPF, hippocampal formation; CA, Cornu Ammonis; DG, dentate gyrus; NCTX, neocortex; AMY, Amygdala; AAA, Anterior
amygdalar area; CEAm, Central amygdalar area, medial part; MEAad, Medial amygdalar area, anterodorsal part; MEApd, Medial amygdalar area, posterodorsal part;
MEApv, Medial amygdalar area, posteroventral part; COApl, Cortical amygdalar area, posterior part; COApm, Cortical amygdalar area, posterior part, medial zone;
PA, posterior amygdalar nucleus; BMAa; Basomedial amygdalar nucleus, anterior part; PIR, piriform cortex; CLA, claustrum; EPd, endopiriform nucleus, dorsal part.
Scalebars: (A) 500 µm, (B,D) 100 µm, and (C) 250 µm.
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regions in order to define the expression pattern in diverse cell
populations (Table 1). The intensity of immunoreactivity varied
in different regions and neuronal populations.
Telencephalon
Olfactory Areas
The olfactory regions presented a very typical labeling (Figure 2).
In the main olfactory bulb, mitral cells were found strongly
positive for Elovl5 staining. In the superficial part of the outer
plexiform layer small cells, likely tufted cells, showed moderate
Elovl5 labeling, whereas no positive cells were observed in
the granular layer (Figure 2A). The accessory olfactory bulb
presented a similar expression pattern with a strong staining in
the mitral cells (Figure 2D). In anterior olfactory nucleus positive
cells for Elovl5 were found mainly in layer II (Figure 2C), whereas
in the olfactory tuberculus in layers II and III (Figure 2D).
Hippocampal Formation
Elovl5 immunolabeling was expected to be extremely strong in
this region, because of the high signal obtained with the XGal
staining (Figure 1A). Immunofluorescence analysis confirmed a
relatively strong labeling of pyramidal neurons, but with regional
differences (Figure 3A). In fact, in all hippocampal fields Elovl5
labeling was clearly present in pyramidal neurons, with a gradient
of intensity: the signal was stronger in CA2 and CA3 than in
CA1 and subiculum, where it was just moderately intense. Several
neurons of the strata oriens and radiatum were strongly labeled.
Hilar neurons also showed a strong Elovl5 staining. Neurons
of the dentate gyrus were negative, with the exception of a few
strongly labeled cells in the subgranular zone.
Neocortex, Claustrum, and Amygdala
The cerebral neocortex showed a layer-specific expression pattern
(Figure 3B). Cells showing moderately strong Elovl5 labeling
were found in layer II/III, IV and V. In layer VI neurons
displayed a weak intensity staining. In the corpus callosum,
sparse positive cells were found. The piriform and endopiriform
cortex showed a strong Elovl5 labeling (Figure 3C), whereas
claustrum displayed a moderate intensity labeling (Figure 3C).
In the amygdala, neurons showed a moderate reactivity for Elovl5
in general: more prominent in the cortical regions than in medial
ones (Figure 3D).
Basal Ganglia
Caudate, putamen and nucleus accumbens presented a weak
fluorescence signal for Elovl5 staining, with just few sparse
cells with a very strong labeling. Whereas, the globus pallidus
displayed a strong signal for Elovl5 immunofluorescence staining
in both internal and external parts. The subthalamic nucleus was
strongly labeled. The substantia nigra pars compacta and the
ventral tegmental area showed a strong labeling (Table 1).
Diencephalon
Thalamus
The reticular nucleus of the thalamus showed the most
prominent labeling for Elovl5, compared to the other
nuclei (Figure 4). The peripeduncular nucleus also showed
a strong labeling. The parvicellular part of subparafascicular
nucleus, geniculate complex and ventral posteromedial and
FIGURE 4 | Distribution of Elovl5 in thalamus. Elovl5 (green) expression in the
thalamus has a region-specific intensity. The most intense labeling is shown
by the reticular nucleus. LGd, dorsal part of lateral geniculate complex; LGv,
ventral part of lateral geniculate complex; MG, medial geniculate complex;
SPFp, subparafasciular nucleus, parvicellular part; PP, peripeduncular
nucleus; ZI, zona incerta; VPM, Ventral posteromedial nucleus of thalamus;
VPL, Ventral posterolateral nucleus of thalamus; RT, Reticular nucleus of
thalamus. Scale bar: 200 µm.
posterolateral nuclei of the thalamus presented instead moderate
immunoreactivity to Elovl5 staining (Figure 4 and Table 1).
In the zona incerta there was a strong labeling (Figure 4 and
Table 1).
Hypothalamus
In the hypothalamus, the tuberal nucleus, retrochiasmatic
area and anterior hypothalamic nucleus displayed the most
prominent labeling for Elovl5 compared to the other structures
belonging to this region. The lateral hypothalamic area showed
a heterogenous expression pattern: the immunofluorescence
signal was stronger in the rostral part of the nucleus while
it had a weaker intensity in the caudal part (Table 1).
Supramammillary and lateral mammillary nuclei, as well as
lateral preoptic area presented a moderate immunoreactivity to
Elovl5 antibody.
Brainstem
The Elovl5 expression pattern was very complex in the brainstem.
The brainstem together with the cerebellum showed the highest
intensely labeled cells (Table 1).
Midbrain
The inferior colliculus displayed weak or no labeling for Elovl5,
whereas the superior colliculus showed a moderate signal. The
most prominent labeling in this region was in the red nucleus.
The periaqueductal gray and the midbrain reticular nucleus
displayed moderate labeling (Table 1).
Pons
The tegmental nuclei showed the most prominent labeling for
Elovl5 (Figure 5A). Pontine nuclei, tegmental reticular nucleus
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FIGURE 5 | Elovl5 expression in pons and medulla. (A) In the pons, the most
prominent labeling for Elovl5 is shown by tegmental nuclei, while pontine
nuclei, tegmental reticular nucleus and superior olivary complex displayed a
moderately strong signal. Medium-low intensity is shown by pontine reticular
nuclei. (B) In the medulla, very strong labeling for Elovl5 is shown by medial
vestibular nucleus and spinal vestibular nucleus. A moderate to weak signal is
detected in the nucleus of the solitary tract, intermediate reticular nucleus and
gigantocellular reticular nucleus. A non-homogeneous pattern of expression is
present in the paragigantocellular reticular nucleus and medullary reticular
nucleus. (A) LDT, Laterodorsal Tegmentel Nucleus; PCN, Pontine Central
Nuclei; PRNc, Pontine Reticular Nucleus, caudal part; PRNr, Pontine Reticular
Nucleus, rostral part; TRN, Tegmental Reticular Nucleus; PN, Pontine Nuclei;
SOC, Superior olivary Complex. (B) MV, Medial Vestibular Nucleus; SPIV,
Spinal Vestibular Nucleus; NTS, Nucleus of Solitary Tract; IRN, Intermediate
reticular Nucleus; GNR, Gigantocellular Reticular nucleus; PGNR,
Paragigantocellular Reticular nucleus; MDRN, Medullary Reticular nucleus.
Scale bars: (A) 200 µm and (B) 250 µm.
and superior olivary complex displayed a strong presence of
positive cells too (Figure 5A). The pontine reticular nuclei were
found to be moderately and non-homogeneously positive for
Elovl5 labeling (Figure 5A and Table 1).
Medulla
The medial vestibular nucleus and spinal vestibular nucleus
presented a very strong labeling for Elovl5 (Figure 5B). The
nucleus of the solitary tract, intermediate reticular nucleus
and gigantocellular reticular nucleus showed moderate to weak
reactivity to Elovl5 antibody. The paragigantocellular reticular
nucleus and medullary reticular nucleus, instead, displayed a
peculiar pattern of expression: in both areas, the Elovl5 signal
was not homogeneous (Figure 5B). In the paragigantocellular
reticular nucleus, the parvicellular part showed a more prominent
expression compared to the magnocellular one (Figure 5B).
In the medullary reticular nucleus the most intense signal was
presented by neurons with bigger cell body compared to smaller
ones, except for the fiber tract, in which small cells, probably
oligodendrocytes, displayed an incredible high signal for Elovl5
labeling. The inferior olivary complex showed strong staining for
Elovl5 (Table 1).
Cerebellum
In adult cerebellum the immunofluorescence labeling for Elovl5
reflected faithfully the XGal staining (Figure 1B). Purkinje cells
FIGURE 6 | Distribution of Elovl5 in the cerebellum. (A) High magnification of
the cerebellar cortex. Purkinje cells (Pcl) strongly express Elovl5; a moderate
signal is present in sparse positive cells in white matter (wm), deeper part of
the molecular layer (ml) and granular layer (gcl) (white arrow). (B) Prominent
expression of Elovl5 (green) (DAPI in blue) by deep cerebellar nuclei (DCN).
Scale bars: (A,B) 100 µm.
Frontiers in Neuroanatomy | www.frontiersin.org 8 April 2021 | Volume 15 | Article 669073
fnana-15-669073 April 24, 2021 Time: 18:18 # 9
Balbo et al. Central Nervous System Expression of Elovl5
FIGURE 7 | Elovl5 in the spinal cord. (A) Schematic representation of a spinal cord coronal section and areas magnified showed in panels (B–D). (B,C) Elovl5
(green) is strongly expressed by small cells in the spinal cord white matter and in a moderate way by motor neurons in the gray matter. (D) High magnification of large
neurons of the dorsal horn, positive for Elovl5 staining (green). (B,C) wm, white matter; gm, gray matter. Scale bars: (B,C) 100 µm and (D) 50 µm.
showed a strong positivity in cell bodies (Figure 6A) with
no differences in the expression pattern between anterior and
posterior lobules (Hoxha et al., 2017). The labeling was present
also in some sparse neurons in the granular layer, in the
deeper part of the molecular layer and cerebellar white matter
(Figure 6A). Interestingly, deep cerebellar nuclei displayed the
most intense labeling (Figure 6B).
Spinal Cord
In the spinal cord, Elovl5 showed a well distinguishable cell-
type expression pattern (Figures 7A–D). In fact, by analyzing
the gray matter, motor neurons belonging to laminae VIII and
IX presented a moderate intensity signal for Elovl5 staining
(Figure 7B). From laminae I to VII, instead, cells displayed very
weak labeling. The most prominent expression seemed to belong
to glial cells in the white matter (Figures 7C,D).
Elovl5 Expression in Glial Cells
In each analyzed region of the CNS Elovl5 immunoreactivity was
not restricted to neurons, but rather comprises glial cells, whose
immunophenotyping was in most cases hampered by the slice
treatments required for anti-Elovl5 immunostaining (see section
“Materials and Methods”). Thus, in order to identify Elovl5
positive glial cell types, double immunofluorescence staining
was performed on primary cell cultures and on sagittal mouse
brain sections. Elovl5 was expressed by virtually all immature
oligodendrocyte precursor cells (identified by the expression of
the chondroitin sulfate proteoglycan AN2; Boda et al., 2011) and
by oligodendrocytes (expressing the myelin basic protein, MBP)
in vitro (Figures 8A–C). Notably, Elovl5 mRNA level appeared
remarkably increased in oligodendrocytes compared to immature
OPCs (Figure 9A, P < 0.05 Mann-Whitney U-test), suggesting
Elovl5 participation in oligodendroglia maturation. Elovl5
immunolabeling was also found in microglial cells, identified by
expression of ionized calcium-binding adapter molecule 1 (Iba1)
(Figure 8D). In these cells, Elovl5 mRNA expression showed
a non-significant tendency to increase when microglia were
polarized toward a proinflammatory M1 phenotype, compared to
resting microglia (Figure 9B). In contrast, microglia polarization
toward a proregenerative M2 phenotype was not associated to
changes in Elovl5 transcript levels (Figure 9B). Finally, while
most astrocytes showed no or little immunolabeling for Elovl5,
a subpopulation of glial fibrillary acidic protein (GFAP) positive
astrocytes was found positively marked (Figures 8E,F).
DISCUSSION
The present study provides for the first time, to our knowledge,
a comprehensive description of Elovl5 cell- and region-specific
localization in the adult mouse brain. By immunohistochemistry,
we showed that there are no rostro-caudal and ventro-dorsal
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FIGURE 8 | Elovl5 expression in glial cells. (A–C) Widespread distribution of Elovl5 (red) in cultured AN2+ (green) oligodendrocyte precursor cells (A) and in maturing
(B) and differentiated ramified (C) MBP+ (green in B-C) oligodendrocytes. (D) Elovl5 (green) expression in cultured Iba1+ (red) microglia. (E,F) Sagittal brain slices
showing low and heterogeneous expression of Elovl5 (green) in GFAP+ (red) astrocytes. White arrowheads in (E) point to negative cells. Yellow arrowheads in (F)
point to Elovl5+ cells. Scale bars: 10 µm.
differences in the expression of Elovl5 throughout the brain.
Interestingly, big soma projecting neurons (e.g., mitral cells,
cerebellar Purkinje cells, and cortical/hippocampal pyramidal
cells) and glial cells showed a prominent expression of Elovl5.
XGal staining and immunohistochemistry revealed subtle
discrepancies between Elovl5 promoter activity and Elovl5
protein expression. Indeed, we observed that the XGal staining
was very strong and homogeneous in the hippocampal pyramidal
neurons, while the fluorescent signal was only moderately intense
in CA2 and CA3 pyramidal cells and lower in the other
hippocampal fields. On the other hand, in the thalamus, XGal
analysis showed a low signal, while the fluorescent signal was
stronger in all thalamic nuclei. These results suggest the existence
of transcriptional or post-transcriptional regulation of Elovl5
expression. Notably, it is reported that estrogens can act as
negative regulators of miRNAs which downregulate Elovl5 at a
post-trascriptional level (Zhang et al., 2017).
Elovl5 distribution in distinct CNS areas and in specific
cell types suggests a unique role of this enzyme in the local
synthesis of PUFAs subserving specific neuronal/glial processes
and CNS functions. In the olfactory areas of the telencephalon,
mitral cells showed the most prominent expression of Elovl5
protein, in contrast with a lack of labeling in the granular layer.
Furthermore, strong positivity for Elovl5 was found in pyriform
cortex, olfactory tubercle and anterior olfactory nucleus, which
are part of the olfactory system. These findings are in line with
the loss of the sense of smell found in SCA38 patients and
in Elovl5−/− mice (Borroni et al., 2016; Hoxha et al., 2017),
suggesting a crucial role of Elovl5 in olfaction, in line with the
reported importance of PUFAs availability for a correct olfactory
discrimination and a proper olfactory tissue integrity (Greiner
et al., 2001; Le Bon et al., 2018; Khoury et al., 2020).
A pattern similar to the olfactory bulb was also observed in the
cerebellar cortex. Purkinje cells were strongly positive for Elovl5,
whereas granular cells were negative. This expression pattern
well correlates with the gait abnormality and balance deficits
observed in SCA38 patients with ELOVL5 mutation and in the
Elovl5−/− mouse model (Borroni et al., 2016; Hoxha et al., 2017).
By studying this pathological mouse model, it has been shown
that the absence of Elovl5 in Purkinje cells led to a shrinkage of
the dendritic tree causing molecular layer atrophy (Hoxha et al.,
2017). This evidence suggests an important role of Elovl5 for
the correct maintenance of Purkinje cell dendritic morphology,
a necessary requirement for cerebellar function.
In the hippocampus, Elovl5 showed a peculiar expression
pattern: labeling was specific for pyramidal cells and interneurons
of the strata oriens and radiatum. The involvement of PUFAs
in hippocampal synaptic plasticity has been largely described in
the literature (Fukaya et al., 2007; Cutuli et al., 2014; Thomazeau
et al., 2017) suggesting that the Elovl5 expression in this region is
required for proper functioning and refinement of the circuits.
The characterization of Elovl5 expression in the brainstem
was challenging because of the huge density of cells and nuclei.
In general, the most prominent labeling was shown by nuclei
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FIGURE 9 | Gene expression analysis of Elovl5 in glial cells. (A) Elovl5
expression in oligodendrocytes (OL, n = 4) compared to immature
oligodendrocyte precursor cells (OPC, n = 4) (P < 0.05 Mann-Whitney U-test).
(B) Elovl5 levels in microglial cells in resting (M0, n = 3), proinflammatory M1
phenotype (n = 3) and proregenerative M2 phenotype (n = 3). The expression
levels were compared to the microglial cells in resting state. *P < 0.05.
functionally and anatomically connected to the cerebellum (e.g.,
the red nucleus in the midbrain and the vestibular nuclei
in the medulla).
An interesting finding is that Elovl5 expression is not
restricted to neurons but is extended to glial cells. The expression
by both mature and immature oligodendrocytes suggests that
Elovl5 downstream products might be important players in
myelination and other oligodendroglia functions.
Along with oligodendrocytes, microglial cells showed a
prominent expression of Elovl5, consistent with the observation
that some Elovl5 downstream products, omega-3 PUFAs,
play a major role in the resolution of neuroinflammation
and in enhancing beneficial immune response (Ebert et al.,
2009; Chen et al., 2014; Joffre et al., 2019). Astrocytes
instead showed no or little Elovl5 immunolabeling. However,
a subpopulation of astrocytes was found positively marked,
suggesting a local regulation of fatty acid production that
could be possibly exploited for signaling or expansion of local
membranes in astrocytes (Sakers et al., 2017). Furthermore, it
has been recently shown that, while undergoing a neurogenic
program, some astrocytes need to upregulate genes encoding
for enzymes essential for lipid metabolisms, including Elovl5
(Magnusson et al., 2020).
The expression pattern of Elovl5 in the CNS is similar
to the expression of Elovl4 (Sherry et al., 2017). Mutations
of ELOVL5 or ELOVL4 cause spinocerebellar ataxia 38 and
34, respectively (Ozaki et al., 2015; Borroni et al., 2016) with
common neurological symptoms which might be explained by
the regional expression similarity between the two enzymes.
Interestingly, both enzymes are expressed in neurons and glial
cells. Elovl5 is expressed by oligodendroglial cells, microglia and
is heterogeneously in vivo expressed by astrocytes while Elovl4 is
reported to be weakly expressed by astrocytes and presumably by
oligodendrocytes (Sherry et al., 2017).
However, their cell-specific expression differs in some brain
areas. In the cerebellum Elovl5 is expressed by Purkinje cells but
not granule cells while Elovl4 is expressed mainly by granule
cells with a low positivity in Purkinje cells (Sherry et al., 2017).
Furthermore, in the olfactory bulb Elovl5 is expressed by mitral
cells but not by granule cells while Elovl4 is expressed the most
by granule cells with a low expression by mitral cells (Sherry
et al., 2017). It is not clear how this difference in expression
determines the onset of some neurological symptoms which are
specific for SCA38 or SCA34, for instance the hyposmia in the
SCA38 patients (Borroni et al., 2016).
Overall, the region-/cell-specific expression of Elovl5 suggests
a special requirement of local production of VLCF with signaling
or structural functions, in specific neuronal and glial cell types.
However, further functional studies are needed to dissect the
context-dependent role of Elovl5 and of its downstream products
in neural cell physiology.
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